Shionogi
Shionogi & Company, Limited (塩野義製薬株式会社, Shionogi Seiyaku Kabushiki Kaisha) is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses Shionogi ("シオノギ").
 | |
| Type | Public (K.K) |
|---|---|
| TYO: 4507 Nikkei 225 Component | |
| Industry | Biotechnology & Pharmaceuticals |
| Founded | Osaka, Japan (March 17, 1878) |
| Founder | Gisaburo Shiono, Sr. |
| Headquarters | 1-8, Doshomachi 3-chome, Chuo-ku, Osaka 541-0045, Japan |
Key people | |
| Products | |
| Revenue |  $ 3.009 billion USD (FY 2012)(¥ 282.904 billion JPY) (FY 2012) |
| $709.79 million USD (FY 2012) (¥ 66.728 billion JPY) (FY 2012) | |
Number of employees | Consolidated : 6,082 |
| Website | Official website |
| Footnotes / references [1][2] | |
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough (merged in 2009 with Merck & Co) to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.[3]
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.[4]
Medicines
- Avelox, antibacterial antiseptic that treats a number of infections.
- Claritin, An anti-histamine marketed in alliance with Schering-Plough.
- Crestor, cholesterol drug , marketing rights sold to AstraZeneca in 1998.
Shionogi Headquarters in Osaka - Cymbalta, an SNRI class anti-depressant, marketed in alliance with Eli Lilly.
- Differin (developed by Galderma), a topical retinoid for acne, marketed in Japan in alliance with Galderma.
- Fortamet
- Methlyin
- Mogadon, a short-term treatment for insomnia.
- Mulpleta, a thrombopoietin receptor agonist.
- Osphena, an estrogen receptor agonist, marketing rights sold to Duchesnay in 2017.[5]
- Symproic, a μ-opioid receptor antagonist, for opioid-induced constipation treatment.
- Xofluza, an endonuclease inhibitor, for influenza treatment.
Media
- Shionogi has a close relationship with Fuji Television Network, Inc., because Shionogi is the sponsor of "Music Fair" (as of 2021, aired on 17 TV stations including TV Oita System Co.) started in 1964.
- Shionogi was a main sponsor of Team Lotus in the team's final years between 1991 to 1994.[6]
References
- "Shionogi Company Profile". Retrieved 18 March 2014.
- "Shionogi Annual Report 2013" (PDF). Retrieved 18 March 2014.
- "Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio". viivhealthcare.com. Retrieved 18 March 2014.
- "Components:Nikkei Stock Average". Nikkei Inc. Retrieved 11 March 2014.
- "Duchesnay acquires Osphena from Shionogi Inc" (Press release). Duchesnay. 10 March 2017. Archived from the original on 24 October 2019. Retrieved 23 October 2019.
- Perry, Alan. "Sponsor Company Profiles". Retrieved 25 April 2012.
External links
- Official Website (in English)
- Official U.S. Website (in English)
